When was Athersys founded?

Athersys was founded in 1995 and raised its 1st funding round 5 years after it was founded.

Where is Athersys located?

Athersys is headquartered in Cleveland, United States.

How many employees does Athersys have?

As of Mar 31, 2026, the latest employee count at Athersys is 35.

Is Athersys a funded company?

Athersys is a funded company, having raised a total of $74.4M across 15 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on May 08, 2000.

When was the latest funding round of Athersys?

Athersys' latest funding was a $***** Post IPO round on Mar 30, 2020, with participation from 1 investor. Its primary sector is Diversified Pharmaceuticals. In United States, the Diversified Pharmaceuticals sector has seen $85.4M in funding in 2026 to date.

What is the annual revenue of Athersys?

Annual revenue of Athersys is $5.32M as on Dec 31, 2022.

Where does Athersys rank among its competitors?

Athersys ranks 67th amongst 1338 active competitors, of which 93 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Johnson & Johnson, which secured $34M in Feb, 2025.

Who are the top competitors of Athersys?

Athersys' top competitors include AbbVie, Amgen and Gilead. Among them, Johnson & Johnson secured the most recent funding round in February, 2025.

Athersys - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Athersys engaged in the discovery and development of therapeutic product candidates to treat different cardiovascular, neurological, inflammatory diseases. Its product portfolio includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications such as Ischemic stroke, Acute myocardial infarction, Inflammatory bowel disease. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.

Website: www.athersys.com
Social

Key Metrics

Founded Year

1995

Location

Cleveland, United States

Stage

Public

Total Funding

$74.4M in 15 rounds

Latest Funding Round

Post IPO, Mar 30, 2020, $*****

Investors

Ignite 500 & 19 more

Ranked

67^th among 1338 active competitors

Annual Revenue

$5.32M as on Dec 31, 2022

Employee Count

35 as on Mar 31, 2026

Similar Companies

Ensoma & 79 more

Exit Details

Public

View Athersys' full profile

Athersys is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Athersys, Inc / New CIN: 1368148 , United States, Active	Jan 08, 2019	$5.32M (As on Dec 31, 2022)	24 (As on Dec 31, 2022)	-
Athersys, Inc. CIN: 341830213 , United States, Active		-	13 (As on Dec 31, 2023)	-

Athersys got listed on Jun 12, 2007.

Click here to take a look at Athersys's IPO in detail

Athersys has raised a total funding of $74.4M over 15 rounds. Its first funding round was on May 08, 2000. Its latest funding round was a Post IPO round on Mar 30, 2020 for $*****. 1 investor participated in its latest round. Athersys has 20 institutional investors.

Here is the list of recent funding rounds of Athersys:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 30, 2020	4656187	Post IPO	8950654	2710526	4514856	5506389
Nov 26, 2019	8318148	Post IPO	9422944	1646268	7542428	Aspire Capital
Aug 15, 2017	7337880	Grant (prize money)	1439988	7966646	3244134	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Athersys's funding rounds and investors

Athersys' employee count trend

Athersys has 35 employees as of Mar 26. Here is Athersys's employee count trend over the years:

Uncover Athersys' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Athersys include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Athersys, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Amgen Business Development, Gershon Capital ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Temasek & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Gershon Capital & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, Castle Investment Management ... & 16 others	76/100
6th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
7th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Alcor Fund, Benson Family Private Equity ... & 16 others	72/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 7 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Gershon Capital & 7 others	71/100
10th	Novartis 1996, Basel (Switzerland), Public	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, MT Capital & 9 others	70/100
67th	Athersys 1995, Cleveland (United States), Public	Stem Cell Therapy for the treatment of cardiovascular disease areas	$74.4M	Ignite 500, Western Technology Investment ... & 18 others	52/100